Monoclonal antibodies in neuroinflammatory diseases

Expert Opinion on Biological Therapy

Volumn 13, Issue 6, 2013, Pages 831-846

  Klotz, Luisa ^a   Wiendl, Heinz ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Alemtuzumab; Daclizumab; Inflammatory neuropathy; Monoclonal antibodies; Multiple sclerosis; Natalizumab; Neuromyelitis optica; Rituximab

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEMTUZUMAB; ATACICEPT; AZATHIOPRINE; BELIMUMAB; BETA1A INTERFERON; BIIB 033; DACLIZUMAB; ECULIZUMAB; ETANERCEPT; GNBAC1; INFLIXIMAB; INTERFERON BETA SERINE; IXEKIZUMAB; MEDI 551; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MOR 103; NATALIZUMAB; OCRELIZUMAB; OFATUMUMAB; PALIFERMIN; PREDNISONE; RITUXIMAB; SECUKINUMAB; TABALUMAB; TOCILIZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB; ANTIINFLAMMATORY AGENT;

ADD ON THERAPY; ANKYLOSING SPONDYLITIS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APHTHOUS STOMATITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE HEPATITIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILL; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CHRONIC LYMPHATIC LEUKEMIA; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CROHN DISEASE; CRYOGLOBULINEMIA; DEMYELINATING NEUROPATHY; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FLU LIKE SYNDROME; GINGIVITIS; GRAFT REJECTION; GRAVES DISEASE; HEADACHE; HERPES ZOSTER; HUMAN; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IGM ANTIMYELIN ASSOCIATED GLYCOPROTEIN NEUROPATHY; IMMUNOSUPPRESSIVE TREATMENT; INCLUSION BODY MYOSITIS; INFUSION RELATED REACTION; JC VIRUS; MALAISE; MEASLES; MONOTHERAPY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYELOOPTIC NEUROPATHY; MYOSITIS; NATURAL KILLER CELL; NERVOUS SYSTEM INFLAMMATION; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PLASMAPHERESIS; POLYMYOSITIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSOAS ABSCESS; PSORIASIS; PSORIASIS VULGARIS; PYOGENIC GRANULOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SJOEGREN SYNDROME; SPIROCHAETAL GINGIVITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T CELL LEUKEMIA; T LYMPHOCYTE ACTIVATION; TUBERCULOSIS; ULCERATIVE COLITIS; ANIMAL; IMMUNOLOGY; NERVOUS SYSTEM DISEASES; NEUROMYELITIS OPTICA; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; HUMANS; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYOSITIS; NERVOUS SYSTEM DISEASES; NEUROMYELITIS OPTICA; TREATMENT OUTCOME;

EID: 84877890808     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.767329     Document Type: Review

References (106)

1. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010;10(5):301-16
2. Buttmann M. Treating multiple sclerosis with monoclonal antibodies: A 2010 update. Expert Rev Neurother 2010;10(5):791-809
3. Katrych O, Simone TM, Azad S, Mousa SA. Disease-modifying agents in the treatment of multiple sclerosis: A review of long-term outcomes. CNS Neurol Disord Drug Targets 2009;8(6):512-19
4. Stuve O, Gold R, Chan A, et al. alpha4-integrin antagonism with natalizumab: Effects and adverse effects. J Neurol 2008;255(Suppl 6):58-65
5. Niino M, Bodner C, Simard ML, et al. atalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 2006;59(5):748-54
6. Lindberg RL, Achtnichts L, Hoffmann F, et al. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol 2008;194(1-2):153-64
7. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354(9):899-910
8. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348(1):15-23
9. Miller DH, Soon D, Fernando KT, et al. RI outcomes in a placebo-controlled trial of natalizumab in relapsing M . Neurology 2007;68(17):1390-401
10. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354(9):911-23
11. Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353(4):375-81
12. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354(9):924-33
13. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab- associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366(20):1870-80
14. Vinhas de Souza M, Keller-Stanislawski B, Blake K et al.Drug-induced PML: A global agenda for a global challenge. Clin Pharmacol Ther 2012;91(4):747-50
15. Bozic C, LaGuette J, Panzara MA, Sandrock AW. Natalizumab and central nervous system lymphoma: No clear association. Ann Neurol 2009;66(3):261-2
16. Zecca C, Nessi F, Bernasconi E, Gobbi C. Ocular toxoplasmosis during natalizumab treatment. Neurology 2009;73(17):1418-19
17. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: Evidence from monoclonal antibody therapy. J Neurol 2006;253(1):98-108
18. Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359(17):1786-801
19. Coles AJ, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999;354(9191):1691-5
20. Moreau T, Thorpe J, Miller D, et ale Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 1994;344(8918):298-301
21. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 2012;78(14):1069-78
22. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet 2012;380(9856):1819-28
23. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet 2012;380(9856):1829-39
24. Costelloe L, Jones J, Coles A. Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. Expert Rev Neurother 2012;12(3):335-41
25. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999;46(3):296-304
26. Jones JL, Coles AJ. Spotlight on alemtuzumab. Int MS J 2009;16(3):77-81
27. Tur C, Montalban X. Subcutaneous alemtuzumab for multiple sclerosis. Expert Rev Clin Immunol 2012;8(5):423-6
28. Gutierrez-Aguirre CH, Cantu-Rodriguez OG, Borjas-Almaguer OD, et al. Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease. Haematologica 2012;97(5):717-22
29. Perumal JS, Foo F, Cook P, Khan O. Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis. Mult Scler 2012;18(8):1197-9
30. Lutterotti A, Martin R. Getting specific: Monoclonal antibodies in multiple sclerosis. Lancet Neurol 2008;7(6):538-47
31. Sandrini S. Use of IL-2 receptor antagonists to reduce delayed graft function following renal transplantation: A review. Clin Transplant 2005;19(6):705-10
32. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006;103(15):5941-6
33. Martin JF, Perry JS, Jakhete NR, et al. An IL-2 paradox: Blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells. J Immunol 2010;185(2):1311-20
34. Wuest SC, Edwan JH, Martin JF, et al. A role for interleukin-2 transpresentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med 2011;17(5):604-9
35. Wynn D, Kaufman M, Montalban X, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): A phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010;9(4):381-90
36. Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 2012;366(21):2008-16
37. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006;6(5):394-403
38. Cardarelli PM, Quinn M, Buckman D, et al. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 2002;51(1):15-24
39. Gurcan HM, Keskin DB, Stern JN, et al. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 2009;9(1):10-25
40. Kotani T, Takeuchi T, Kawasaki Y, et al. Successful treatment of cold agglutinin disease with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus. Lupus 2006;15(10):683-5
41. Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007;66(4):470-5
42. Paues J, Vrethem M. Fatal progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma treated with rituximab. J Clin virol 2010;48(4):291-3
43. Piccio L, Naismith RT, Trinkaus K, et al. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol 2010;67(6):707-14
44. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358(7):676-88
45. Barun B, Bar-Or A. Treatment of multiple sclerosis with anti-CD20 antibodies. Clin Immunol 2012;142(1):31-7
46. Bar-Or A, Calabresi PA, Arnold D, e al. Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial. Ann Neurol 2008;63(3):395-400
47. Naismith RT, Piccio L, Lyons JA, et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial. Neurology 2010;74(23):1860-7
48. Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebocontrolled multicenter trial. Ann Neurol 2009;66(4):460-71
49. Kausar F, Mustafa K, Sweis G, et al. Ocrelizumab: A step forward in the evolution of B-cell therapy. Expert Opin Biol Ther 2009;9(7):889-95
50. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011;378(9805):1779-87
51. Zhang B. Ofatumumab. mAbs 2009;1(4):326-31
52. Pawluczkowycz AW, Beurskens FJ, Beum PV, et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): Considerably higher levels of CDC are induced by OFA than by RTX. J Immunol 2009;183(1):749-58
53. Fernandez O, Alvarez-Cermeno JC, Arroyo-Gonzalez R, et al. Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II). Rev Neurol 2012;54(12):734-49
54. Gross JA, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000;404(6781):995-9
55. Mok MY. The immunological basis of B-cell therapy in systemic lupus erythematosus. Int J Rheum Dis 2010;13(1):3-11
56. Tak PP, Thurlings RM, Rossier C, et al. Atacicept in patients with rheumatoid arthritis: Results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 2008;58(1):61-72
57. Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: Lessons from failed and interrupted treatment trials. BioDrugs 2002;16(3):183-200
58. Brok HP, van Meurs M, Blezer E, et al.Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody. J Immunol 2002;169(11):6554-63
59. Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003;421(6924):744-8
60. Vaknin-Dembinsky A, Balashov K, Weiner HL. IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J Immunol 2006;176(12):7768-74
61. Segal BM, Constantinescu CS, Raychaudhuri A, et al. Repeated subcutaneous injections of IL12/ 23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: A phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008;7(9):796-804
62. Rich P, Sigurgeirsson B, Thaci DP, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: A randomised, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 2012; [Epub ahead of print]
63. Genovese MC, Durez P, Richards HB, et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: A phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 2012; [Epub ahead of print]
64. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366(13):1190-9
65. Wiendl H. Neuroinflammation: The world is not enough. Curr Opin Neurol 2012;25(3):302-5
66. de Seze J, Lebrun C, Stojkovic T, e al. Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. Mult Scler 2003;9(5):521-5
67. Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010;17(8):1019-32
68. Bonnan M, Valentino R, Olindo S, et al.Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler 2009;15(4):487-92
69. Watanabe S, Misu T, Miyazawa I, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: A retrospective analysis. Mult Scler 2007;13(8):968-74
70. Cree BA, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005;64(7):1270-2
71. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: Retrospective analysis of 25 patients. Arch Neurol 2008;65(11):1443-8
72. Capobianco M, Malucchi S, di Sapio A, et al. Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease). Neurol Sci 2007;28(4):209-11
73. Uzawa A, Mori M, Arai K, et al. Cytokine and chemokine profiles in neuromyelitis optica: Significance of interleukin-6. Mult Scler 2010;16(12):1443-52
74. Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA 2011;108(9):3701-6
75. Rother RP, Rollins SA, Mojcik CF, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007;25(11):1256-64
76. Tradtrantip L, Zhang H, Saadoun S, et al. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol 2012;71(3):314-22
77. Renaud S, Gregor M, Fuhr P, et al. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 2003;27(5):611-15
78. Pestronk A, Florence J, Miller T, et al. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003;74(4):485-9
79. Dalakas MC, Rakocevic G, Salajegheh M, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 2009;65(3):286-93
80. Ruegg SJ, Fuhr P, Steck AJ. Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. Neurology 2004;63(11):2178-9
81. Marsh EA, Hirst CL, Llewelyn JG, et al. Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. J Neurol 2010;257(6):913-19
82. Chaudhry V, Cornblath DR. An open-label trial of rituximab (Rituxan(R)) in multifocal motor neuropathy. J periphe Nerv Syst 2010;15(3):196-201
83. Stieglbauer K, Topakian R, Hinterberger G, Aichner FT. Beneficial effect of rituximab monotherapy in multifocal motor neuropathy. Neuromuscul Disord 2009;19(7):473-5
84. De Bleecker JL, Meire VI, Declercq W, Van Aken EH. Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromuscul Disord 1999;9(4):239-46
85. Hengstman GJ, van den Hoogen FH, Barrera P, et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: Preliminary observations. Eur Neurol 2003;50(1):10-15
86. Hengstman GJ, De Bleecker JL, Feist E, et al. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 2008;59(3-4):159-63
87. Dastmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008;67(12):1670-7
88. Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 2011;70(3):427-36
89. Prinz JC. Autoimmune-like syndromes during TNF blockade: Does infection have a role? Nat Rev Rheumatol 2011;7(7):429-34
90. Stubgen JP. Tumor necrosis factor-alpha as a potential therapeutic target in idiopathic inflammatory myopathies. J Neurol 2011;258(6):961-70
91. Sultan SM, Ng KP, Edwards JC, et al. Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy. Clin Exp Rheumatol 2008;26(5):887-93
92. Arlet JB, Dimitri D, Pagnoux C, et al. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Disord 2006;16(5):334-6
93. Sem M, Molberg O, Lund MB, Gran JT. Rituximab treatment of the anti-synthetase syndrome: A retrospective case series. Rheumatology (Oxford) 2009;48(8):968-71
94. Mahler EA, Blom M, Voermans NC, et al. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology (Oxford) 2011;50(12):2206-13
95. Couderc M, Gottenberg JE, Mariette X, et al. Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: Results from the AIR registry. Rheumatology (Oxford) 2011;50(12):2283-9
96. Stubgen JP. Targeted immunotherapy trials for idiopathic inflammatory myopathies. J Neurol 2012; [Epub ahead of print]
97. Hak AE, de Paepe B, de Bleecker JL, et al. Dermatomyositis and polymyositis: New treatment targets on the horizon. Neth J Med 2011;69(10):410-21
98. Dalakas MC, Rakocevic G, Schmidt J, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 2009;132(Pt 6):1536-44
99. Narazaki M, Hagihara K, Shima Y, et al. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford) 2011;50(7):1344-6
100. Gordon PA, Winer JB, Hoogendijk JE, Choy EH. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 2012;8:CD003643
101. Collongues N, Casez O, Lacour A, et al.Rituximab in refractory and non-refractory myasthenia: A retrospective multicenter study. Muscle Nerve 2012;46(5):687-91
102. Diaz-Manera J, Martinez-Hernandez E, Querol L, et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 2012;78(3):189-93
103. Nowak RJ, Dicapua DB, Zebardast N, Goldstein JM. Response of patients with refractory myasthenia gravis to rituximab: A retrospective study. Ther Adv Neurol Disord 2011;4(5):259-66
104. Fox RJ, Miller DH, Phillips JT, et al.Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367(12):1087-97
105. Gold R, Kappos L, Arnold DL, et al.Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367(12):1098-107
106. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365(14):1293-303